President Trump has vowed to impose tariffs on China, Mexico, and Canada. They could make common medicines less affordable.

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...

On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.